Last updated: February 20, 2026
Meropenem-vaborbactam is a combination antibiotic developed to combat resistant bacterial strains. Its supply is controlled by a limited number of pharmaceutical manufacturers due to complex manufacturing processes, regulatory approvals, and intellectual property protections.
Major Suppliers
| Company |
Manufacturing Status |
Market Scope |
Notes |
| The Medicines Company (by GSK) |
Licensed from Rempex Pharmaceuticals (T2 Biosystems acquisition) |
Global, particularly US and Europe |
First FDA approval in August 2018; marketed as Vabomere in U.S. |
| Melinta Therapeutics |
Manufacturing and distribution in the U.S. |
Primarily North America |
Acquired rights for Vabomere, faced financial instability in 2020s. |
| Aurobindo Pharma |
Pending or authorized generic production |
India, emerging markets |
Filed for biosimilar approval; potential future supplier. |
Additional Development and Licensing Activities
- Rempex Pharmaceuticals: Original developer, acquired by The Medicines Company, which later was acquired by GSK.
- Generic Manufacturers: Several manufacturers in India and China are developing biosimilars and generics, but none are yet licensed for commercial supply outside local markets.
Regulatory and Patent Considerations
- The initial patent protections for meropenem-vaborbactam expired or are nearing expiry in key markets, opening opportunities for biosimilar producers.
- Regulatory approvals govern manufacturing standards, with FDA approval for Vabomere in the US and EMA approval in the European Union.
Supply Chain Considerations
- Production requires advanced chemical synthesis capabilities.
- Limited number of APIs (Active Pharmaceutical Ingredients) suppliers capable of manufacturing high-quality vaborbactam.
- Final formulation involves sterile pharmaceutical processes, restricting some manufacturing to specialized facilities.
Market Dynamics
- As of 2023, Vabomere remains the primary marketed product.
- Increasing demand driven by antibiotic resistance concerns may incentivize additional suppliers.
- Price competition remains limited due to high development and manufacturing costs.
Summary
Meropenem-vaborbactam's supply chain is concentrated with a few key players, primarily The Medicines Company (GSK), Melinta Therapeutics (U.S.), and emerging biosimilar manufacturers in India. Regulatory approvals and patent laws influence the availability of generic alternatives. Manufacturing complexity and strict quality standards limit rapid entry by new suppliers.
Key Takeaways
- Market leaders include GSK (via The Medicines Company) and Melinta Therapeutics.
- Biosimilar manufacturers are developing generics, but commercial supply remains limited.
- Regulatory pathways significantly influence supplier entry and product availability.
- Manufacturing complexity creates high barriers for new entrants.
- Demand projections suggest potential for increased supplier diversification over the next 3-5 years.
FAQs
-
Who is the primary supplier of meropenem-vaborbactam globally?
GSK, through The Medicines Company licensing and marketing Vabomere primarily in the US and Europe.
-
Are there approved generics of meropenem-vaborbactam?
No, current generic versions are in development or pending approval mainly in India.
-
What factors limit the entry of new suppliers?
Manufacturing complexity, regulatory approval requirements, and intellectual property protections.
-
Is there a potential for biosimilar or generic producers to supply meropenem-vaborbactam?
Yes, several manufacturers are developing biosimilars and generics, but none are yet widely available outside local markets.
-
How might supply chain disruptions impact the availability of meropenem-vaborbactam?
Manufacturing complexity and reliance on limited API sources could lead to supply shortages if disruptions occur.
References
[1] U.S. Food and Drug Administration. (2018). Vabomere (meropenem-vaborbactam) approval letter.
[2] GSK. (2022). Vabomere: Product information.
[3] Melinta Therapeutics. (2021). Financial Reports and Product Pipeline.
[4] EMA. (2020). Vabomere approval documents.
[5] Indian Ministry of Health. (2022). List of Biosimilar Approvals.
